47 results about "Low glucose" patented technology

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

Disclosed herein are formulations (including sweet proteins and rare sugars) for improving the sweetness of low glycemic index rare sugars without altering the texture and flavor of the rare sugars and methods for improving the sweetness of rare sugars. More specifically, the present invention discloses methods for improving the sweetness of rare sugars without altering the sweetness profile, texture and flavor of the primary sugars. The invention also discloses the addition of Brazitame protein with liquid rare sugars at different temperatures during the synthesis of the rare sugars, before crystallization or before or after caramelization of the rare sugars, to increase sweetness. The Brazilian sweet protein increases the sweetness of rare sugars, but is not limited to D-psicose, D-tagatose, D-allose, isomaltulose, trehalose, sorbose, pinose, leucobiose and the like. The invention also provides for the evaluation of non-nutritional sweeteners (such as aspartame, acesulfame, sodium cyclamate, neotame, saccharin, sucralose, stevioside, etc.), as each has a limitation of taste quality if used with rare sugars. However, the use of Brazilian sweet protein does not alter the flavor and texture of rare sugars, and the taste profile matches sucrose.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention provides a production method for increasing the yield of maltose, which comprises the following steps: proportioning, liquefying and saccharifying, controlling the concentration of starch milk through proportioning, reducing the concentration of syrup, improving the flowability of a system, obtaining a liquefied liquid with a low DE value in the liquefying process, and simultaneously adjusting the pH values of different reaction steps, so that the yield of maltose is increased. Finally, after saccharification is completed, the ultrahigh malt syrup which is low in content of glucose, maltose trisaccharide, maltose trisaccharide or more and high in maltose content is obtained, and the highest maltose content can reach 93%.

The invention discloses prebiotic soft fried dough twists and a making method thereof, and belongs to the technical field of food. The fried dough twist disclosed by the invention is prepared from the following raw materials in parts by mass: 132 to 169.5 parts of a dough base material, 5 to 6 parts of resistant dextrin, 7 to 9 parts of fructo-oligosaccharide microcapsules, 6 to 8 parts of isomaltitol, 1.5 to 2 parts of stachyose, 0.5 to 1.0 part of soybean lecithin and 0.01 to 0.03 part of vitamin E. The prebiotic retention rate is synergistically increased through microcapsule coating and a making process, the aging resistance of the fried dough twist is improved through synergistic moisturizing of resistant dextrin and fructo-oligosaccharide microcapsules, white granulated sugar is partially replaced by isomaltitol, stachyose and other sugar parts with low glycemic index, and the taste of the fried dough twist is improved. And the resistant dextrin with high dietary fiber content and the fructo-oligosaccharide prebiotics are matched, so that the product not only meets the sweet taste requirement, but also meets the healthy diet pursuit of modern consumers on low sugar, high fiber and high prebiotics.

This invention discloses a low glycemic index (GI) Hericium erinaceus (monkey head mushroom) steamed bun, belonging to the field of food processing and functional food applications. By weight, it is prepared from the following raw materials: 45-55 parts all-purpose flour, 28-35 parts Hericium erinaceus extract powder, 0.3-0.35 parts yeast, 15-18 parts water, 0.3-0.6 parts oil, and 0.7-0.9 parts sugar. This invention partially replaces the flour with Hericium erinaceus extract powder, fully utilizing the multiple mechanisms of action of Hericium erinaceus polysaccharides in forming a viscous gel in the digestive tract to slow down the contact between amylase and substrate, inhibiting α-amylase and α-glucosidase activity, and improving intestinal microecology and enhancing insulin sensitivity through dietary fiber. This allows the product to meet the low-GI food standard (GI<55), effectively filling the gap in low-GI steamed buns with Hericium erinaceus functional components as the core active ingredient. It has significant application value in the fields of diabetes management, weight control, and healthy staple foods.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The invention discloses low glycemic index rice flour of a starch-fat-protein ternary complex, and relates to the technical field of food. The low-glycemic-index rice flour is prepared by mixing rice flour, lauric acid and beta lactoglobulin, the preparation process is simple and convenient to operate, the nutritional structure of traditional rice flour is optimized, the glycemic index is lower than that of the traditional rice flour, and the low-glycemic-index rice flour has good nutritional and health-care values.

A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

The application discloses application of a hypoglycemic peptide in preparation of a medicine for inhibiting alpha-amylase and alpha-glucosidase activity. The hypoglycemic peptide is derived from Hericium erinaceus, and the amino acid sequence is AVFPSIVGRPR. The polypeptide is extracted and purified from Hericium erinaceus fruiting body protein, the amino acid sequence of one hypoglycemic peptide is determined by LC-MS / MS, the alpha-amylase inhibition rate is 71.86%±0.08% through hypoglycemic activity detection, and the alpha-glucosidase inhibition rate is 61.52%±0.15%, so the hypoglycemic peptide can be used as a natural hypoglycemic peptide and has a potential application prospect in the field of preparation of medicines for reducing blood sugar and the like.

The application belongs to the technical field of medicine, and discloses a kind of optical compound and its preparation method and application, specifically discloses the enantiomer has different effect.In vitro experiment, enantiomer shows selectivity to target point, S-isomer tends to activate PPARγ, and R-isomer tends to activate FFAR1.In animal model, the efficacy of enantiomer also shows difference, first, two enantiomers can significantly reduce the blood sugar of animal, and significantly improve the insulin resistance of animal.However, in reducing blood triglyceride, the effect of S-isomer is obviously superior to racemate and R-isomer, and in reducing blood cholesterol, the effect of R-isomer is obviously superior to racemate and S-isomer.Therefore, (S)‑1 has important role in preparing blood sugar reducing, triglyceride reducing drug, and (R)‑1 has more significant effect in reducing blood sugar, reducing cholesterol, and has important significance for clinical targeted treatment and application.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a total nutrient formula food with a low glycemic index and a preparation method thereof. The food is prepared from the following raw materials: 50 to 250 parts of concentrated whey protein powder, 40 to 150 parts of soybean protein isolate, 200 to 450 parts of fat powder, 150 to 300 parts of maltodextrin, 150 to 280 parts of cassava dextrin and 10 to 100 parts of resistant dextrin. The weight part ratio of the concentrated whey protein powder to the soybean protein isolate is (1-5): (0.8-1). According to the full-nutrition formula food with the low glycemic index, maltodextrin, cassava dextrin and resistant dextrin are specifically compounded, fructose with potential risk is abandoned, the GI value of the product is reduced to 55 or below, it is ensured that the energy supply ratio of protein, fat and carbohydrate and fatty acid composition meet the requirements of a specific dietary guide, and the low glycemic index is obtained. Unification of stable blood sugar control and comprehensive nutrition supply is realized.

The invention discloses mushroom and lucid ganoderma wine and a brewing method thereof.The mushroom and lucid ganoderma wine is prepared from 260-300 kg of rice wine, 430-470 kg of distilled liquor, 6-12 kg of mushrooms, 1-5 kg of lucid ganoderma, 2-7 kg of milkvetch roots, 2-7 kg of Chinese wolfberry fruits, 1-5 kg of mulberries, 6-12 kg of cistanche deserticola and 250-300 kg of cold boiled water according to 1000 kg of finished products. The lentinus edodes and lucid ganoderma wine brewed by the method integrates the effects of various medicinal and edible food materials such as the sticky rice, the lentinus edodes, the lucid ganoderma and the astragalus membranaceus, and has relatively high nutritional and medicinal values; the effects of resisting cancer, enhancing human immunity, tonifying qi, soothing the nerves, relieving cough and asthma, supporting healthy energy, protecting the liver, resisting fatigue, delaying senescence, reducing blood sugar, promoting circulation, expanding blood vessels, reducing blood cholesterol and triglyceride and the like can be achieved.

A method for adjusting insulin comprises the steps of: an analysis apparatus acquiring carbohydrate intake data, continuous blood glucose data, and insulin administration data; the analysis apparatus determining a meal time point on the basis of the continuous blood glucose data; the analysis apparatus setting, as a pre-meal blood glucose value, a minimum blood glucose value during a preset period before the meal time point; and the analysis apparatus determining, on the basis of the pre-meal blood glucose value, the amount of insulin to be injected.

The invention discloses an insulin infusion control method and system based on an insulin pump, and belongs to the technical field of insulin pump control. The method comprises the steps that user basic data and user blood glucose data and motion data within a preset time period are obtained, and the obtained data are preprocessed; inputting the preprocessed multi-dimensional data into the trained blood glucose prediction model, and predicting the blood glucose change trend of the user in a period of time in the future; adjusting the basic rate of an insulin pump based on the blood glucose change trend; the system comprises a data acquisition module, a data processing module, a data analysis module and an adjustment module. By adopting the method and the system, the intelligent control model is constructed by fusing multi-dimensional data to predict the blood glucose change trend of the user, so that the insulin infusion basic rate is dynamically and accurately adjusted, the blood glucose fluctuation risk is reduced, and the treatment safety and comfort of a patient are improved.

The invention discloses a processing method of frozen minced fillet with low sweetness and low glycemic index (GI). According to the mass ratio of frozen surimi needing to be processed, 3-6% of psicose, 1-2% of oligosaccharide and 1-2% of sorbitol are subjected to ternary compounding to serve as a protein water-retaining and anti-freezing core, 0.1-0.2% of sodium tripolyphosphate, 0.1-0.2% of sodium pyrophosphate and 0.02-0.06% of sodium hexametaphosphate are compounded to provide a stable dissolution and delivery environment, the sodium hexametaphosphate and the psicose are dissolved in water to prepare a solution A, and the solution B is prepared into a solution C; sodium tripolyphosphate and sodium pyrophosphate are dissolved in water to prepare a solution B, a mixed solution of the solution A and the solution B is a low-GI buffer antifreeze agent, oligosaccharide and sorbitol are directly added, the mixture is uniformly mixed with the dehydrated surimi in a carbon dioxide refrigeration vacuum mixer, and the frozen surimi with low sweetness and low glycemic index (GI) is prepared, so that the effects of replacing cane sugar, reducing weight and improving efficiency are realized, and the quality of the surimi is improved. The freeze-resistant minced fillet has excellent freeze resistance and good gel quality, meanwhile, the sweetness is remarkably reduced, the original delicious flavor of the minced fillet is reduced, heat is reduced, sugar rising is controlled, the definite low-GI health attribute is achieved, and the healthy diet requirement of consumers can be met.

Provided are methods for treating patients with type 1 diabetes, wherein the patient has new onset type 1 diabetes no more than eight months before starting treatment, and has not previously received an immunomodulatory agent. Also provided are methods for improving cell health in a patient having type 1 diabetes. Also provided are methods for preserving residual C-peptide in a patient having type 1 diabetes. The methods comprise administering an effective amount of a pharmaceutical therapy that comprises eflornithine while the patient is maintained on a low polyamine diet, wherein the method prevents, delays, decreases the likelihood of, or decreases the severity of diabetic ketoacidosis severe hypoglycemia, progression of diabetic nephropathy and retinopathy.

The invention belongs to the field of new application of medicines, and particularly relates to application of Nrf2-ARE / hMAO-B / QR2 modulator 1 in preparation of a medicine for treating non-alcoholic fatty liver disease. The compound is a multi-target ligand based on resveratrol, and can act on Nrf2-ARE, hMAO-B and QR2 signal channels at the same time. Experimental results show that the compound can significantly reduce the weight of NAFLD mice induced by high fat diet, reduce liver lipid accumulation, improve insulin resistance, reduce blood sugar and liver enzyme level, and relieve liver fatty degeneration and vacuolation pathological changes. In addition, the action mechanism is related to regulation and control of Aldh3a2 gene expression and downstream target protein GPCPD1 of the Aldh3a2 gene expression. The application value of the compound in prevention and treatment of the non-alcoholic fatty liver disease is disclosed for the first time, and a new strategy is provided for developing a multi-target medicine for resisting the non-alcoholic fatty liver disease.

Method for non-intrusive, needle-free detection of severe hypoglycemia onset through assessment of the cerebral arteriovenous oxygen difference. The method primarily pertains to the treatment of high-risk younger patients with Type 1 Diabetes Mellitus (T1DM) experiencing nocturnal hypoglycemia in order to prevent so called “Death in Bed” syndrome-the sudden death of young diabetic patients without any history of long-term complications.

The application discloses application of a Hericium erinaceum hypoglycemic peptide in preparation of a medicine for inhibiting alpha-amylase and alpha-glucosidase activity. The amino acid sequence of the hypoglycemic peptide is AGLQFPVGR. The polypeptide is extracted and purified from Hericium erinaceum fruiting body protein, the amino acid sequence of one hypoglycemic peptide is determined through LC-MS / MS, the alpha-amylase inhibition rate is 75.82%+ / -0.12% and the alpha-glucosidase inhibition rate is 63.33%+ / -0.28% through hypoglycemic activity detection, so the hypoglycemic peptide can be used as a natural hypoglycemic peptide and has a potential application prospect in the field of preparation of a medicine for reducing blood sugar and the like.

The invention provides microencapsulated Omega-3 reinforced rice noodles with a low glycemic index and a preparation method of the microencapsulated Omega-3 reinforced rice noodles. The microencapsulated Omega-3 reinforced rice noodles with the low glycemic index are prepared from the following components in parts by weight: 50.5 to 65.5 parts of early indica rice flour, 12 to 16 parts of mung bean starch, 6 to 10 parts of vital gluten, 8 to 12 parts of high-resistance rice flour, 2 to 7 parts of white kidney bean extract, 1.5 to 5 parts of fish oil powder, 0.3 to 0.8 part of table salt and 18 to 22 parts of water. Wherein the microencapsulated fish oil powder is composed of a maltodextrin wall material and a fish oil powder core material, the maltodextrin wall material accounts for 25-35% of the microencapsulated fish oil powder, and the fish oil powder core material accounts for 65-75% of the microencapsulated fish oil powder. The high-resistance starch, the white kidney bean extract and the microencapsulated fish oil powder are scientifically compounded, the glycemic index is remarkably reduced, the glycemic index GI value is smaller than or equal to 55, 250-900 mg of DHA + EPA is provided for every 100 g of finished products, the fishy smell is effectively masked through the microencapsulation technology, the eating quality is improved, and the product quality is improved. And a staple food with functions of controlling sugar and protecting heart is provided for people suffering from diabetes, patients suffering from cardiovascular diseases and people suffering from hypertension, hyperglycemia and hyperlipidemia.

The present application relates to a pharmaceutical composition for intranasal administration of glibenclamide and a preparation method thereof, the pharmaceutical composition of glibenclamide of the present application solves the technical problem of low drug concentration in the brain and the side effect of easily causing severe hypoglycemia, the pharmaceutical composition of the present application significantly improves the solubility of the drug, realizes higher concentration in the brain without increasing the risk of hypoglycemia, improves the brain targeting, and has better compliance.

The application discloses a preparation method and application of a walnut peptide with alpha-glucosidase inhibitory activity. The oligopeptide comprises the following amino acid sequences: VVDW and / or FAGDDAPRA. The walnut oligopeptide can be applied to the preparation of an alpha-glucosidase inhibitor or a medicine for reducing blood sugar or a medicine for delaying postprandial blood sugar rise or a medicine or food for improving diabetes. The oligopeptide in the application has excellent inhibitory activity on alpha-glucosidase, and the half-inhibitory concentration can reach 220.8 micromoles. The oligopeptide has the ability to efficiently inhibit alpha-glucosidase activity at a lower concentration, the risk of toxic side effects or allergic reactions of the oligopeptide can be greatly reduced at a lower working concentration, the safety is better, and the oligopeptide has a good drug-making prospect.

The invention provides a composition for reducing a glycemic index and application of the composition, and belongs to the technical field of functional foods and health-care products. The composition provided by the invention comprises the following components in parts by weight: 15-68 parts of branched chain amino acid (BCAA) and 0.1-6 parts of taurine. The branched chain amino acid and the taurine in the composition can protect pancreatic beta cells, promote insulin secretion and improve insulin resistance, insulin sensitivity, expression and translocation of glucose transporters and the like. In addition, the branched chain amino acid in the composition can enable insulin to recover to a normal level, and normal secretion and carbohydrate homeostasis of the insulin of the body are guaranteed. The composition disclosed by the invention can reduce the glycemic index from multiple dimensions, also can ensure the absorption of high protein and the intake of high-quality carbonated water, is more beneficial to the simultaneous intake of multiple nutrients by an organism, and maintains the health of the organism.

The application discloses a novel anti-diabetic factor and application thereof, and belongs to the technical field of biological medicine and microbial fermentation. The application first discovers a naturally existing glucose oxidase AnGOD-HHS from a specific and non-genetically modified Aspergillus niger ACCC 30177. The glucose oxidase has high specific activity, high thermal stability, and high activity under low oxygen conditions, effectively ensures the enzymolysis activity of the AnGOD-HHS under a low oxygen environment, reduces the risk of serious hypoglycemia caused by the sharp fluctuation of catalytic efficiency, and improves the safety and reliability of treatment.

The present invention relates to a low-sugar gochujang prepared to contain beneficial components through lactic acid bacteria, particularly postbiotics which are dead cells, while preventing the progression of additional fermentation to prevent off-flavors and overflow of contents. More specifically, the invention relates to a method for manufacturing low-sugar gochujang and low-sugar gochujang prepared using the same, wherein a substitute sugar, dietary fiber, and lactic acid bacteria (dead cells) are mixed in a predetermined ratio to maximize the beneficial components of the lactic acid bacteria, thereby enabling the consumption of said beneficial components without loss through the low-sugar gochujang, and which is characterized by the prevention of adult diseases and chronic diseases due to the low-sugar content. By manufacturing a low-sugar gochujang with a structure similar to a fermented jam or fermented spread that maximizes beneficial components and is made with low sugar, the intake of beneficial insoluble dietary fiber is enhanced, while retaining the characteristics of lactic acid bacteria (postbiotics) and preventing the overflow of contents caused by the generation of off-flavor and fermentation gas, thereby activating the immune function of normal human cells to suppress the proliferation and recurrence of cancer cells, reducing blood sugar and blood cholesterol, and improving lipid metabolism to suppress the formation and accumulation of body fat.

The invention discloses mutagenic rhizobium pulsatilla for producing beta-1, 3-glucan at high yield as well as a preparation method and application of the mutagenic rhizobium pulsatilla, and belongs to the technical field of biology. The bacterial strain is rhizobium pusta RSFBMT-41666, and the preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) No.36520 The preparation method comprises the following steps: screening the rhizobium pustatae wild strain A414 from soil, carrying out 12C < 6 + > heavy ion beam irradiation and low-temperature plasma combined mutagenesis, and carrying out Congo red identification plate preliminary screening and shake flask fermentation secondary screening to obtain the rhizobium pustatae wild strain A414. The mutant strain takes glucose as a main carbon source, the yield of a fermentation product beta-1, 3-glucan reaches 31.4 g / L and is increased by 56% compared with that of a wild strain, the purity is 95.40%, and the mutant strain is excellent in water solubility and has special rheological properties. The problems that an existing strain is high in carbon source cost and low in glucose utilization efficiency are solved, the industrial production cost is reduced, and the product has wide application prospects in the fields of food, medicine and cosmetics.

The invention relates to the technical field of functional food, and discloses glutamine composition formula food suitable for diabetics and a preparation method of the glutamine composition formula food suitable for the diabetics. Comprising the following raw materials: glutamine-theanine microcapsules, maltodextrin, mulberry leaf extract powder, an antioxidant composition, mogroside, citric acid, malic acid and an anti-caking agent. Wherein the glutamine-theanine microcapsule is a microcapsule which is obtained by taking sodium caseinate and carrageenan as wall materials and glutamine and theanine in tea leaves as core materials and carrying out spray drying treatment on the wall materials and the core materials. And the product is not easy to lose efficacy and has a relatively long shelf life.